ABVC Biopharma Issues Amendment to Recent SEC Filing
I'm PortAI, I can summarize articles.
ABVC Biopharma Inc. has amended its Form 8-K/A report, initially filed on April 30, 2025. The amendment includes details about a purchase agreement and a voting rights proxy agreement, signed by CEO Uttam Patil on January 16, 2026. This information was published via the SEC's EDGAR system and is intended for informational purposes only, not as financial or legal advice.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments